BIOTECH ASSISTANT / FIELD NOTES

Pharmaron reports nine-month revenue growth of 19.01%

Regulatory / securities filing · 康龙化成 / 巨潮资讯 CNinfo

Source published: 2026-10-28 · Event / reporting date: 2026-09-30

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Pharmaron reported consolidated revenue of RMB12.003 billion, up 19.01%, and attributable net income of RMB1,247.1 million for the nine months ended September 30, 2026. CDMO revenue rose 31.72%, while new CDMO orders increased more than 40%. The quarterly filing is unaudited and covers the year-to-date period.

Why it may matter

Order growth supports the demand outlook, but delivery timing, margins, and cash collection remain necessary checks.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

China-listed CRO/CDMO

Related updates

2026-11-02Fresenius

Fresenius gains development options on up to 37 WuXi Biologics biosimilar candidates

Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.

China-listed CRO/CDMO Ask AI ↗

2026-10-30百奥赛图 / 巨潮资讯 CNinfo

Biocytogen reports nine-month revenue growth of 49.09%

Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.

China-listed CRO/CDMO Ask AI ↗

2026-10-30药石科技 / 巨潮资讯 CNinfo

PharmaBlock Sciences reports nine-month revenue growth of 15.16%

PharmaBlock Sciences reported consolidated revenue of RMB1.634 billion, up 15.16%, and attributable net income of RMB151.2 million for the nine months ended September 30, 2026. Attributable net income rose 33.36%, while net cash from operations declined 53.75% over the same period. The quarterly filing is unaudited and covers the year-to-date period.

China-listed CRO/CDMO Ask AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗